Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-24T17:06:53.277Z Has data issue: false hasContentIssue false

Follow-up results in tuberculous cervical lymphadenitis

Published online by Cambridge University Press:  25 November 2005

Mehmet F Oktay
Affiliation:
Department of Otolaryngology, Dicle University Medical School, Diyarbakir, Turkey
Ismail Topcu
Affiliation:
Department of Chest Diseases, Dicle University Medical School, Diyarbakir, Turkey
Abdurrahman Senyigit
Affiliation:
Department of Radiology, Dicle University Medical School, Diyarbakir, Turkey
Aslan Bilici
Affiliation:
Department of Pathology, Dicle University Medical School, Diyarbakir, Turkey
Adem Arslan
Affiliation:
Department of Otolaryngology, University of Minnesota, Minneapolis, Minnesota, USA
Sebahattin Cureoglu
Affiliation:
Department of Otolaryngology, Dicle University Medical School, Diyarbakir, Turkey
Muzeyyen Yildirim
Affiliation:
Department of Chest Diseases, Dicle University Medical School, Diyarbakir, Turkey

Abstract

Objective: To investigate the efficacy of medical antituberculous treatment in patients with tuberculous cervical lymphadenitis (TCL).

Methods: In the period 1996–2002, 73 TCL patients were reviewed and the results of clinical and laboratory testing were documented. The efficacy of a four-drug chemotherapy regimen was investigated.

Results: Purified protein derivatives (PPD) skin test results were positive in 58 (79 per cent) patients. Chest X-rays revealed changes consistent with tuberculosis in nine (12.3 per cent) patients. The mean duration of medical treatment was 10.04 months. In follow-up evaluation, 14 (20 per cent) patients were considered suspicious for resistant TCL and total excision of all nodes was performed. Histopathology confirmed TB in only 10 of these cases.

Conclusion: The high incidence of residual disease in our study indicates that medical treatment (at least nine months of four combined antituberculous drugs) did not seem to be effective. If lymphadenopathy persists, total surgical excision of lymph nodes should be the treatment of choice.

Type
Main Articles
Copyright
© 2005 JLO (1984) Limited

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

This paper was presented at the annual American Academy of Otolaryngology and Head and Neck Surgery Foundation (AAO–HNSF) meeting, 19–22 September 2004, New York, New York, USA.